Sun Pharmaceutical Industries Ltd.
NSE: SUNPHARMA
Healthcare · Drug Manufacturers - Specialty & Generic
₹1,748.00 last close on 23 Oct 2026 −0.57%
Research updated
Eris Lifesciences Ltd.
NSE: ERISHealthcareDrug Manufacturers - Specialty & Generic
- Last close
- ₹1,095.50
- Day change
- −₹25.70 (−2.29%)vs
- Market cap
- ₹15,877 crIndian rupees
- Research updated
- 1 report
Follow Eris Lifesciences
Create an account, then follow this company for weekday briefs. You will return to Eris Lifesciences after signing in.
About Eris Lifesciences
Eris Lifesciences Ltd. is a prominent pharmaceutical company engaged in the development, manufacturing, and distribution of a wide array of pharmaceutical products. Established with the goal of enhancing healthcare accessibility, Eris focuses on various therapeutic areas, including cardiology, diabetology, gastroenterology, and dermatology, providing crucial medications to address lifestyle and chronic conditions. The company plays a significant role in the healthcare industry by innovating and delivering high-quality drug formulations to the market. Based in India, Eris Lifesciences Ltd. caters primarily to domestic demand, but its impact is growing beyond national boundaries as it explores international markets. Known for its robust marketing strategies and strong distribution network, the company effectively reaches healthcare practitioners, ensuring that patients receive timely access to essential medications. Eris Lifesciences Ltd.'s dedication to research and development, combined with a strategic focus on key therapeutic segments, underscores its contribution to advancing medical treatments and improving patient outcomes in the pharmaceutical sector.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Listing
- NSE: ERIS
- Next results
- Employees
- 2,758
- Headquarters
- Ahmedabad, India
- ISIN
- INE406M01024
- Website
- eris.co.in
Public research · Report of
Business model & financial foundation
Eris Lifesciences (NSE: ERIS), Pharmaceuticals - Indian branded formulations: revenue of ₹3,129 crore in FY26 (+8.1% on FY25), an EBITDA margin of 35.8%, net profit of ₹619.5 crore and net debt of ₹2,255 crore.
- Revenue, FY26 (₹ crore)
- 3,129
- consolidated
- Revenue growth, FY26
- +8.1%
- on FY25
- EBITDA margin, FY26
- 35.8%
- EBITDA (Operating EBITDA excluding other income) / revenue
- Net profit, FY26 (₹ crore)
- 619.5
- to owners
- Return on equity, FY26
- 17.3%
- on average equity
- Net debt, FY26 (₹ crore)
- 2,255
- Company disclosed net debt (see basis limitations)
- Market capitalisation (₹ crore)
- 18,060
- at the close of 16 Oct 2026
Company profile
Eris Lifesciences is an Ahmedabad-based Indian branded formulations company founded in 2007 and listed in 2017, focused on chronic and sub-chronic therapies (diabetes, cardiovascular, dermatology, nephrology, women's health, oncology/critical care). Since FY23 it has grown through acquisitions (Oaknet, Glenmark and Dr Reddy's derma brands, Biocon's nephrology/derma and India insulin/oncology businesses, Swiss Parenterals, BioNxt), adding injectables, insulin and export CDMO capability. FY26 consolidated revenue was Rs3,129 cr.
| Item | Value |
|---|---|
| Legal name | Eris Lifesciences Limited |
| Exchange and ticker | NSE: ERIS; BSE: 540596 |
| ISIN | INE406M01024 |
| CIN | L24232GJ2007PLC049867 |
| Sector | Healthcare |
| Industry | Pharmaceuticals - Indian branded formulations |
| Headquarters | Ahmedabad, India |
| Fiscal year end | March |
| Reporting basis and unit | consolidated, in ₹ crore |
| Auditor | Walker Chandiok & Co LLP (since FY26) |
| Market capitalisation | ₹18,060 crore (16 Oct 2026) |
| Shares outstanding | 13.85 crore shares (FY26) |
| Price | ₹1,149 (close, 16 Oct 2026) |
| 52-week range | ₹1,138 - ₹1,740 (to 16 Oct 2026) |
| Website | https://eris.co.in/ |
Corporate structure and shareholding
| Entity | Holding | Business |
|---|---|---|
| Eris Therapeutics Ltd | 100% | Branded formulations; holds Oaknet and Aprica |
| Eris Healthcare Pvt Ltd | 100% | Group domestic billing and distribution entity |
| Swiss Parenterals Ltd | 100% | Sterile injectables manufacturing and exports (100% from 16 Jan 2026) |
| Eris BioNxt Pvt Ltd | 100% | Injectables/biologics plant (ex-Chemman Labs); holds 30% of Levim Lifetech JV |
| Eris M.J. Biopharm Pvt Ltd | 70% | Manufacturing subsidiary |
| Eris Pharmaceuticals Pvt Ltd | 100% | Subsidiary |
| Eris Oaknet Healthcare Pvt Ltd | 100% | Step-down via Eris Therapeutics; dermatology/branded |
| Aprica Healthcare Ltd | 100% | Step-down via Eris Therapeutics |
| Levim Lifetech Pvt Ltd | 30% | JV (equity method) via Eris BioNxt; GLP-1/biologics |
Promoter-led (Amit Bakshi 42.1% at Mar26); no holding company. A composite scheme involving ETL, Aprica and Oaknet is pending approvals (S5 p350).
| Shareholding (% of shares) | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoter | 54.85% | 54.85% | 53.92% | 54.14% |
| Promoter holding pledged | 16.92% | 16.92% | 16.92% | 16.85% |
| Foreign institutions | 7.21% | 6.85% | 6.39% | 5.76% |
| Domestic institutions | 19.36% | 20.32% | 20.35% | 20.70% |
| of which mutual funds | 17.33% | 18.26% | 18.22% | 18.88% |
| Retail | 9.79% | 9.20% | 10.69% | 10.76% |
| Other | 8.78% | 8.78% | 8.64% | 8.63% |
The promoter holding pledged is a share of the promoter's own holding.
Business model
Eris sells prescription-led domestic branded formulations, predominantly chronic/sub-chronic therapies, with sterile injectable exports through Swiss Parenterals. The consolidated scope is essential: domestic invoicing moved into Eris Healthcare, while acquired Biocon, Swiss and Oaknet businesses are subsidiaries. There is one statutory pharmaceuticals segment; DBF and international are management divisions, not statutory segments. FY26 DBF revenue2,778cr and Swiss348cr sit against consolidated3,129.42cr; management rounding,other operating income and eliminations explain why those columns do not exactly add. Prescription audit sales are not recognised revenue: Sundae's Q1FY27 audit12cr cannot be multiplied into statutory sales without a bridge.
| Peer | Why the dossier compares them |
|---|---|
| Abbott India (ABBOTINDIA) | Domestic branded formulations, chronic/metabolic exposure, premium margins |
| Ajanta Pharma (AJANTPHARM) | Specialist-driven branded India business in cardiac, derma, ophthalmology |
| Alkem Laboratories (ALKEM) | Large India branded formulations player incl. chronic franchise |
| Torrent Pharmaceuticals (TORNTPHARM) | Chronic-heavy India branded leader; inorganic brand-acquisition model; JB Chemicals amalgamated into it effective 8 Jul 2026 (S50) |
| Mankind Pharma (MANKIND) | India branded formulations with acquisition-led expansion (BSV) |
Financial databook
| Profit and loss (₹ crore) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue from operations | 1,326 | 1,662 | 2,009 | 2,894 | 3,129 |
| Cost of revenue (vendor classification) * | 260.8 | 357.1 | 387.6 | 730.1 | 818.2 |
| Other operating costs (vendor classification) * | 338.7 | 436.3 | 527.4 | 616.6 | 609.1 |
| EBITDA (vendor classification) * | 496.8 | 542.8 | 691.9 | 1,033 | 1,127 |
| Operating EBIT excluding other income | 446.3 | 430.8 | 492.2 | 701.7 | 840.6 |
| Finance costs | 4.15 | 26.2 | 84.8 | 231.3 | 192.7 |
| Profit before tax | 442.2 | 404.6 | 431.2 | 488.9 | 638.5 |
| Tax expense / (benefit) | 36.4 | 30.5 | 34.2 | 114.2 | -8.97 |
| PAT including non-controlling interests | 405.8 | 374.2 | 397.1 | 374.7 | 647.5 |
| Diluted EPS (₹) | 29.88 | 28.07 | 28.79 | 25.81 | 45.26 |
| Share of JV profit net of tax included before PBT | n.a. | 0.06 | 0.09 | ||
| Materials, purchases and inventory change | 380.0 | 714.0 | 795.6 | ||
| Employee benefits expense | 403.8 | 505.1 | 556.8 | ||
| Other operating expenses | 550.5 | 657.4 | 656.9 | ||
| Operating EBITDA excluding other income | 674.8 | 1,017 | 1,120 | ||
| Other income | 23.8 | 18.4 | 7.75 | ||
| Depreciation and amortisation | 182.6 | 315.5 | 279.5 | ||
| Exceptional gain / (charge) | 0.00 | 0.00 | -17.2 | ||
| PAT attributable to non-controlling interests | 5.07 | 22.8 | 28.0 | ||
| PAT attributable to owners | 392.0 | 351.8 | 619.5 | ||
| Sale of products and services | 1,991 | 2,879 | 3,115 | ||
| Other operating income | 17.8 | 14.4 | 14.5 | ||
| Cost of materials consumed | 177.8 | 276.3 | 326.7 | ||
| Purchases of stock-in-trade | 201.5 | 473.1 | 490.6 | ||
| Changes in finished goods, WIP and stock-in-trade | 0.72 | -35.5 | -21.6 | ||
| Total income including other income | 2,033 | 2,912 | 3,137 | ||
| Total operating expenses before finance and D&A | 1,334 | 1,876 | 2,009 | ||
| Current tax | 82.2 | 111.8 | 157.4 | ||
| Deferred tax expense / (credit) | -48.0 | 2.36 | -166.4 | ||
| Other comprehensive income / (loss) | -3.05 | -3.29 | -1.44 | ||
| Total comprehensive income | 394.0 | 371.4 | 646.1 | ||
| Basic EPS (₹) | 28.82 | 25.85 | 45.33 |
| Balance sheet (₹ crore) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Total equity including NCI | 1,908 | 2,221 | 3,222 | 3,272 | 3,896 |
| Current and non-current borrowings excluding leases | 84.4 | 876.7 | 2,735 | 2,422 | 2,310 |
| Cash and cash equivalents | 50.9 | 56.0 | 94.2 | 199.7 | 54.7 |
| Trade receivables | 161.0 | 292.7 | 422.0 | 458.6 | 680.3 |
| Inventories | 117.9 | 131.4 | 189.0 | 334.8 | 436.8 |
| Total trade payables | 117.8 | 124.8 | 268.3 | 332.4 | 329.7 |
| Net property plant and equipment excluding ROU/intangibles | 110.1 | 154.0 | 456.2 | 604.9 | 661.5 |
| Capital work in progress | 48.4 | 33.2 | 19.1 | 66.7 | 171.5 |
| Total assets | 2,272 | 3,667 | 7,049 | 7,036 | 7,366 |
| Company disclosed net debt (see basis limitations) | 2,687 | 2,222 | 2,255 | ||
| Other bank balances including restricted deposits | 1,306 | 23.1 | 12.6 | ||
| Current investments | 0.00 | 5.00 | 0.00 | ||
| Non-current investments excluding equity-accounted JV | 15.5 | 10.5 | 9.98 | ||
| Right of use assets | 48.4 | 57.2 | 46.9 | ||
| Goodwill | 861.2 | 912.0 | 912.0 | ||
| Other intangible assets | 2,962 | 3,732 | 3,567 | ||
| Intangible assets under development | 0.61 | 0.27 | 0.00 | ||
| Non-current loans | 1.04 | 1.08 | 1.12 | ||
| Other non-current financial assets | 9.33 | 10.8 | 9.83 | ||
| Non-current income tax assets net | 48.9 | 39.5 | 40.7 | ||
| Deferred tax assets net | 306.9 | 289.0 | 242.9 | ||
| Other non-current assets | 17.8 | 34.2 | 110.6 | ||
| Total non-current assets | 4,747 | 5,810 | 5,826 | ||
| Current loans | 5.56 | 5.78 | 52.8 | ||
| Other current financial assets | 2.22 | 3.19 | 9.08 | ||
| Other current assets | 282.6 | 196.0 | 293.6 | ||
| Total current assets | 2,302 | 1,226 | 1,540 | ||
| Equity share capital | 13.6 | 13.6 | 13.9 | ||
| Other equity | 2,573 | 2,841 | 3,889 | ||
| Equity attributable to owners | 2,586 | 2,854 | 3,903 | ||
| Non-controlling interest in equity | 635.9 | 417.4 | -7.01 | ||
| Non-current borrowings | 654.5 | 1,738 | 955.8 | ||
| Current borrowings | 2,081 | 684.2 | 1,354 | ||
| Non-current lease liabilities | 37.0 | 44.2 | 40.2 | ||
| Current lease liabilities | 8.98 | 12.1 | 8.75 | ||
| Investments accounted using equity method | 51.5 | 51.6 | |||
| Other non-current financial liabilities | 6.28 | 6.40 | 1.07 | ||
| Other non-current liabilities | 1.38 | 4.47 | 3.80 | ||
| Non-current provisions | 52.7 | 69.0 | 86.8 | ||
| Deferred tax liabilities net | 542.8 | 518.5 | 305.1 | ||
| Total non-current liabilities | 1,295 | 2,380 | 1,393 | ||
| Trade payables to micro and small enterprises | 26.6 | 16.0 | 8.76 | ||
| Trade payables to other creditors | 241.7 | 316.4 | 320.9 | ||
| Other current financial liabilities | 23.4 | 165.1 | 197.7 | ||
| Other current liabilities | 49.0 | 69.2 | 71.6 | ||
| Current provisions | 62.0 | 78.1 | 37.7 | ||
| Current income tax liabilities net | 39.6 | 43.6 | 77.8 | ||
| Total current liabilities | 2,532 | 1,385 | 2,077 | ||
| Total liabilities | 3,827 | 3,765 | 3,470 | ||
| Total equity and liabilities | 7,049 | 7,036 | 7,366 | ||
| Separately identified unrestricted liquid investments | n.d. | n.r. | n.r. |
| Cash flow (₹ crore) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Net cash from operating activities after taxes | 383.4 | 243.6 | 486.0 | 1,065 | 538.0 |
| Free cash flow (vendor definition) * | 257.2 | -549.7 | 356.8 | 910.0 | 241.1 |
| Purchase of PPE/intangibles, positive outflow magnitude | -120.3 | -841.3 | 129.2 | 155.0 | 296.9 |
| Dividends paid, positive outflow magnitude | -81.6 | -99.9 | 0.00 | 100.1 | 0.00 |
| Cash generated from operations before taxes | 586.8 | 1,163 | 662.4 | ||
| Net income taxes paid, signed cash flow | -100.8 | -97.9 | -124.4 | ||
| Operating profit before working capital changes | 685.5 | 1,037 | 1,120 | ||
| Cash flow change in trade receivables | -57.1 | -9.11 | -210.3 | ||
| Cash flow change in inventories | -16.9 | -94.4 | -100.7 | ||
| Cash flow change in other assets | -16.2 | 122.0 | -99.5 | ||
| Cash flow change in trade payables | 91.0 | 67.9 | -3.16 | ||
| Cash flow change in financial liabilities | -73.4 | 0.99 | -3.19 | ||
| Cash flow change in provisions | -3.59 | 24.3 | -40.0 | ||
| Cash flow change in other liabilities | -22.4 | 16.8 | 2.37 | ||
| Net cash used in investing activities signed | -1,855 | -80.0 | -369.5 | ||
| Net cash from financing activities signed | 1,380 | -881.3 | -313.5 | ||
| Business combination consideration signed cash flow | -566.8 | -1,169 | -10.0 | ||
| NCI acquisition payments signed cash flow | -10.3 | -237.5 | 0.00 | ||
| Lease payments signed, report-specific scope | -0.89 | -12.2 | -16.9 | ||
| Interest/finance costs paid signed cash flow | -77.3 | -141.6 | -189.1 | ||
| Proceeds from equity issuance under employee options | 4.54 | 7.22 | 4.48 | ||
| Proceeds from sale of PPE | 0.00 | 0.37 | 0.09 | ||
| Government grants received | 3.88 | 0.00 | |||
| Consideration paid for joint venture investment signed | -51.4 | 0.00 | |||
| Mutual fund redemption proceeds, net/report scope | 30.5 | 3.00 | 0.68 | ||
| Proceeds from redemption of bonds | 0.00 | 5.54 | |||
| CCDs purchased from minority interest signed cash flow | 0.00 | -34.7 | |||
| Loans given signed cash flow | -1.65 | -0.25 | -47.0 | ||
| Proceeds/(investment) in bank balances outside cash equivalents | -1,212 | 1,284 | 10.5 | ||
| Interest received signed cash flow | 6.99 | 4.43 | 2.22 | ||
| Proceeds from long-term borrowings | 1,400 | 117.3 | |||
| Long-term borrowing repayments signed cash flow | -798.9 | -282.3 | |||
| Net short-term borrowing proceeds/(repayments) | -998.3 | 53.0 | |||
| Total borrowing proceeds, where not split by tenor | 1,623 | ||||
| Total borrowing repayments, where not split by tenor | -159.4 | ||||
| Net increase/(decrease) in cash | 11.3 | 103.7 | -145.0 | ||
| Cash and equivalents opening balance | 56.0 | 94.3 | 199.7 | ||
| Cash acquired in business combinations | 27.0 | 1.77 | 0.00 | ||
| Cash and equivalents closing balance | 94.2 | 199.7 | 54.7 | ||
| Cash flow change in financial assets | -2.51 | -3.66 |
| Other reported lines (₹ crore) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Year-end issued and fully paid equity shares | 13.59 | 13.60 | 13.60 | 13.62 | 13.85 |
| Weighted average shares for basic EPS | 13.60 | 13.61 | 13.67 | ||
| Weighted average shares for diluted EPS | 13.62 | 13.63 | 13.69 | ||
| Year-end receivable days on annual revenue | 77 | 58 | 79 | ||
| CFO / PAT including NCI (x) | 1.22x | 2.84x | 0.83x | ||
| Receivables year-on-year growth (%) | 8.7% | 48.3% | |||
| Revenue year-on-year growth (%) | 44.0% | 8.1% | |||
| Borrowings + leases - cash (deposit liquidity unverified) | 2,304 | ||||
| Cumulative three-year CFO / cumulative PAT total (x) | 1.47x | ||||
| Contingent liabilities / total net worth (%) | 1.3% |
| Quarterly profit and loss (₹ crore) | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations (incl. other operating income) | 741.2 | 727.5 | 705.3 | 773.0 | 792.4 | 807.5 | 756.6 | 873.3 |
| Cost of revenue (vendor classification) * | 186.3 | 176.9 | 186.4 | 184.6 | 202.4 | 223.3 | 185.3 | 239.3 |
| Other operating costs (vendor classification) * | 164.8 | 174.9 | -193.6 | 167.2 | 164.3 | 164.5 | 160.8 | 184.4 |
| EBITDA (vendor classification) * | 269.1 | 254.5 | 260.4 | 280.3 | 291.3 | 281.8 | 274.6 | 298.2 |
| EBIT (operating EBITDA less D&A; excl. other income, JV) | 184.1 | 169.3 | 175.1 | 206.2 | 219.1 | 211.3 | 204.0 | 224.2 |
| Finance cost | 59.5 | 57.2 | 54.3 | 48.7 | 49.6 | 48.8 | 45.6 | 46.7 |
| Profit before tax | 129.2 | 116.4 | 128.9 | 161.1 | 172.7 | 145.4 | 159.4 | 179.5 |
| Total tax expense | 32.8 | 29.3 | 26.5 | 36.0 | 38.2 | 36.5 | -119.7 | 36.2 |
| Profit after tax (incl. NCI) | 96.4 | 87.1 | 102.4 | 125.1 | 134.5 | 108.8 | 279.1 | 143.3 |
| Diluted EPS (₹) | 6.72 | 6.14 | 6.89 | 8.64 | 8.81 | 7.31 | 20.57 | 10.26 |
| Sale of products | 739.0 | 722.1 | 702.6 | 771.6 | 790.2 | 800.9 | 752.3 | 869.0 |
| Other operating income | 2.22 | 5.33 | 2.70 | 1.44 | 2.26 | 6.56 | 4.27 | 4.22 |
| Cost of materials consumed | 72.2 | 69.4 | 68.3 | 70.1 | 82.6 | 105.9 | 68.1 | 94.3 |
| Purchase of stock-in-trade | 118.4 | 133.2 | 96.0 | 104.3 | 146.1 | 117.2 | 123.0 | 131.1 |
| Changes in inventories (signed, expense positive) | -4.24 | -25.8 | 5.99 | 10.3 | -26.3 | 0.21 | -5.84 | 13.9 |
| COGS (materials + purchases + inventory change) | 186.3 | 176.9 | 170.3 | 184.6 | 202.4 | 223.3 | 185.3 | 239.3 |
| Employee benefits expense | 125.6 | 125.4 | 121.5 | 144.4 | 137.5 | 138.1 | 136.9 | 153.4 |
| Other expenses | 164.8 | 174.9 | 161.2 | 167.2 | 164.3 | 164.5 | 160.9 | 184.4 |
| Operating EBITDA (excl. other income) | 264.5 | 250.3 | 252.4 | 276.7 | 288.2 | 281.6 | 273.6 | 296.2 |
| Other income | 4.55 | 4.22 | 7.95 | 2.69 | 2.81 | 0.02 | 2.23 | 2.39 |
| Depreciation and amortisation | 80.4 | 81.0 | 77.3 | 70.5 | 69.1 | 70.3 | 69.6 | 72.1 |
| Share of JV profit (signed gain; within PBT) | 0.00 | 0.00 | 0.06 | 0.89 | 0.28 | 0.12 | -1.20 | -0.40 |
| Exceptional items (signed: gain +, charge -) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -17.2 | 0.00 | 0.00 |
| Current tax | 30.3 | 24.9 | 31.4 | 56.3 | 71.2 | 17.4 | 12.5 | 31.1 |
| Deferred tax | 2.55 | 4.44 | -4.87 | -20.3 | -33.0 | 19.1 | -132.2 | 5.07 |
| PAT attributable to owners | 91.7 | 83.8 | 93.8 | 118.0 | 120.2 | 99.7 | 281.6 | 142.4 |
| PAT attributable to non-controlling interest | 4.76 | 3.30 | 8.51 | 7.11 | 14.3 | 9.11 | -2.51 | 0.93 |
| Basic EPS (₹) | 6.73 | 6.15 | 6.90 | 8.66 | 8.82 | 7.32 | 20.60 | 10.28 |
Consolidated, as reported. Lines marked * are the market-data provider's figures; the rest are extracted from the company's filings or derived from them. n.d. not disclosed, n.r. not retrieved, n.a. not applicable.
Metrics dashboard
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue growth | 11.2% | 25.3% | 20.9% | 44.0% | 8.1% |
| EBITDA margin | 33.6% | 35.2% | 35.8% | ||
| Net margin | 19.5% | 12.2% | 19.8% | ||
| Return on equity | 14.4% | 10.8% | 17.3% | ||
| Return on capital employed | 25.0% | 16.9% | 10.9% | 12.0% | 14.1% |
| Return on assets | 7.3% | 5.0% | 8.6% | ||
| Net debt (₹ crore) | 2,687 | 2,222 | 2,255 | ||
| Net debt / EBITDA | 3.98x | 2.18x | 2.01x | ||
| Interest cover | 107.6x | 16.5x | 5.80x | 3.03x | 4.36x |
| Asset turnover | 0.65x | 0.56x | 0.37x | 0.41x | 0.43x |
| Receivable days | 44 | 64 | 77 | 58 | 79 |
| Inventory days (on revenue) | 32 | 29 | 34 | 42 | 51 |
| Payable days (on revenue) | 32 | 27 | 49 | 42 | 38 |
| Cash conversion | 1.24x | 3.03x | 0.87x | ||
| Capex intensity | 9.1% | 50.6% | 6.4% | 5.4% | 9.5% |
| Free cash flow (₹ crore) | 263.1 | -597.7 | 356.8 | 910.0 | 241.1 |
| Dividend payout | 0.0% | 28.4% | 0.0% | ||
| EPS, diluted (₹) | 29.88 | 28.07 | 28.79 | 25.81 | 45.26 |
| Book value per share (₹) | 140.4 | 163.3 | 236.9 | 240.3 | 281.2 |
Computed from the statements above:
- Revenue growth: revenue over the previous year's, less one.
- EBITDA margin: EBITDA (Operating EBITDA excluding other income) / revenue.
- Net margin: net profit to owners / revenue.
- Return on equity: net profit to owners / average equity.
- Return on capital employed: EBIT / average equity plus borrowings.
- Return on assets: net profit to owners / average total assets.
- Net debt (₹ crore): Company disclosed net debt (see basis limitations); negative is net cash.
- Net debt / EBITDA: net debt / EBITDA (Operating EBITDA excluding other income).
- Interest cover: EBIT / finance cost.
- Asset turnover: revenue / average total assets.
- Receivable days: receivables / revenue x 365.
- Inventory days (on revenue): inventory / revenue x 365.
- Payable days (on revenue): payables / revenue x 365.
- Cash conversion: cash from operations / net profit to owners.
- Capex intensity: capital expenditure / revenue.
- Free cash flow (₹ crore): cash from operations less capital expenditure.
- Dividend payout: dividends paid / net profit to owners.
- EPS, diluted (₹): as reported (Diluted EPS).
- Book value per share (₹): equity / shares outstanding.
Source: the company's filings and disclosures as extracted into Mool's company dossier (version 1, information to 16 Oct 2026); market data at the close of 16 Oct 2026. Every figure is read from the dossier's files or computed from them; the account of the business model is the analyst's, from the dossier's workings.
With Individual or above
What the full research on Eris Lifesciences includes
Every piece of Mool’s research is built the same way: a researched evidence base, analyses that build on each other, a research model and a report with the call. This page shows the first analysis.
The report and Mool’s call
- The 12-month rating and target
- The 3-month view
- Mool's estimates beside the street's
- The claims the view rests on, and what would change it
The analyses, among them
- Business model & financial foundationOn this pageWhat the company does and how it makes money, its structure, five years of financials and the metrics that matter for it.
- Future earnings & financial modelForecasts built from the drivers that move the business, by scenario, beside the street's.
- Fundamental valuation & 12-month thesisWhat the business is worth on several methods, what the market already prices in and the 12-month thesis that follows.
The research model
The model behind the report: the company’s history, the drivers that move it, its forecasts by scenario and the valuation the 12-month target comes from.
See Mool’s call and the full research
Individual or above opens every piece of research Mool has published. A new account can start with 10 days of Pro, or of Firm on a work email address. No card needed.
Report history
Reports on Eris Lifesciences
- Research reportLatest
Same sector
More research in Healthcare
Divi's Laboratories Ltd.
NSE: DIVISLAB
Healthcare · Drug Manufacturers - Specialty & Generic
₹8,950.00 last close on 23 Oct 2026 −2.31%Research updated
Torrent Pharmaceuticals Ltd.
NSE: TORNTPHARM
Healthcare · Drug Manufacturers - Specialty & Generic
₹4,524.40 last close on 23 Oct 2026 −1.97%Research updated
Apollo Hospitals Enterprise Ltd.
NSE: APOLLOHOSP
Healthcare · Medical Care Facilities
₹7,730.00 last close on 23 Oct 2026 +1.65%Research updated
Lenskart Solutions Limited
NSE: LENSKART
Healthcare · Medical Instruments & Supplies
₹626.45 last close on 23 Oct 2026 −1.23%Research updated
Zydus Lifesciences Ltd.
NSE: ZYDUSLIFE
Healthcare · Drug Manufacturers - Specialty & Generic
₹1,129.40 last close on 23 Oct 2026 −0.49%Research updated
Prices are the last close on the NSE, 23 Oct 2026. Research from Mool’s report of 16 Oct 2026; page updated 25 Oct 2026.
Mool’s research is written by AI agents and published by Mool Capital Private Limited, a SEBI-registered Research Analyst, registration INH000012449, which is responsible for it. This page shows factual company information and an excerpt of that research; it carries no rating and is not investment advice for any individual. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Read the disclosures.